NYSE:PFE - Pfizer Stock Price, News, & Analysis

Question 1

What is Pfizer's stock symbol?

Answer

Pfizer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PFE."

Question 2

How often does Pfizer pay dividends? What is the dividend yield for Pfizer?

Answer

Pfizer declared a quarterly dividend on Thursday, June 28th. Shareholders of record on Friday, August 3rd will be given a dividend of $0.34 per share on Tuesday, September 4th. This represents a $1.36 annualized dividend and a yield of 3.11%. The ex-dividend date of this dividend is Thursday, August 2nd. View Pfizer's Dividend History.

Question 3

How will Pfizer's stock buyback program work?

Answer

Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Tuesday, December 19th 2017, which allows the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company's board believes its shares are undervalued.

Question 4

How were Pfizer's earnings last quarter?

Answer

Pfizer Inc. (NYSE:PFE) issued its quarterly earnings results on Tuesday, July, 31st. The biopharmaceutical company reported $0.81 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.74 by $0.07. The biopharmaceutical company earned $13.47 billion during the quarter, compared to analyst estimates of $13.30 billion. Pfizer had a net margin of 42.35% and a return on equity of 25.35%. The company's revenue was up 4.4% on a year-over-year basis. During the same period in the previous year, the firm posted $0.67 earnings per share. View Pfizer's Earnings History.

Question 5

When is Pfizer's next earnings date?

Answer

Pfizer is scheduled to release their next quarterly earnings announcement on Tuesday, October, 30th 2018. View Earnings Estimates for Pfizer.

Question 6

What guidance has Pfizer issued on next quarter's earnings?

Answer

Pfizer issued an update on its FY18 earnings guidance on Tuesday, July, 31st. The company provided earnings per share guidance of $2.95-3.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.95. The company issued revenue guidance of $53-55 billion, compared to the consensus revenue estimate of $54.25 billion.

Question 7

What price target have analysts set for PFE?

Answer

20 brokerages have issued 1 year price objectives for Pfizer's stock. Their predictions range from $37.00 to $47.00. On average, they anticipate Pfizer's stock price to reach $42.1765 in the next year. This suggests that the stock has a possible downside of 3.7%. View Analyst Price Targets for Pfizer.

Question 8

What is the consensus analysts' recommendation for Pfizer?

Answer

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pfizer in the last year. There are currently 2 sell ratings, 9 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pfizer.

Question 9

What are Wall Street analysts saying about Pfizer stock?

Answer

Here are some recent quotes from research analysts about Pfizer stock:

1. Cantor Fitzgerald analysts commented, ". After speaking with five oncologists, we see two growth drivers for Ibrance that represent meaningful upside to consensus sales and our numbers. These opportunities include: OUS expansion and the use of Ibrance in the earlier-stage adjuvant setting. Our discussions focused on answering the following questions: (1) What is the remaining growth/market penetration opportunity for CDK 4/6s in the currently approved indications?; (2) How much share erosion can we expect from other CDK 4/6s such as How high is physician conviction for PALLAS and How much will positive outcomes increase usage? Below we highlight our key takeaways." (9/13/2018)
2. According to Zacks Investment Research, "Pfizer beat estimates for both earnings and sales in the second quarter. Pfizer is facing top-line headwinds in the form of genericization of key drugs, supply challenges in the legacy Hospira portfolio, pricing pressure and rising competition. Nonetheless, we believe that new products like Ibrance, contribution from acquisitions, cost-cutting efforts, a lower tax rate and share buybacks should help the company achieve its guidance. Pfizer also boasts a strong pipeline and expects approximately 25 to 30 drug approvals through 2022, including around 15 products that have blockbuster potential. Pfizer’s growing immuno-oncology portfolio has strong potential. Bavencio is being considered a key long-term growth driver for Pfizer. In oncology, Pfizer has four potential medicines under FDA’s priority review. The shares have outperformed the industry this year so far." (8/6/2018)

Question 10

Are investors shorting Pfizer?

Answer

Pfizer saw a drop in short interest in the month of August. As of August 31st, there was short interest totalling 48,507,825 shares, a drop of 7.1% from the August 15th total of 52,192,249 shares. Based on an average daily volume of 18,845,697 shares, the days-to-cover ratio is currently 2.6 days. Approximately 0.8% of the company's stock are short sold. View Pfizer's Current Options Chain.

Question 11

Who are some of Pfizer's key competitors?

Answer

Some companies that are related to Pfizer include Johnson & Johnson (JNJ), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Eli Lilly And Co (LLY), Sanofi (SNY), Bristol-Myers Squibb (BMY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bayer (BAYRY), Allergan (AGN), Celgene (CELG) and Shire (SHPG).

Question 12

Who are Pfizer's key executives?

Answer

Pfizer's management team includes the folowing people:

Mr. Ian C. Read, Chairman & CEO (Age 64)
Mr. Frank A. D'Amelio, Exec. VP of Bus. Operations & CFO (Age 60)
Mr. Albert Bourla D.V.M., DVM, Ph.D., COO & Director (Age 56)
Dr. Mikael Dolsten, Pres of Worldwide R&D (Age 59)
Mr. John D. Young, Group Pres of Pfizer Innovative Health (Age 53)

Question 13

Has Pfizer been receiving favorable news coverage?

Answer

News coverage about PFE stock has trended somewhat positive on Thursday, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pfizer earned a daily sentiment score of 0.18 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Pfizer.

Question 14

Who are Pfizer's major shareholders?

Answer

Pfizer's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.65%), Northern Trust Corp (1.28%), Bank of New York Mellon Corp (1.14%), Bank of New York Mellon Corp (1.14%), Massachusetts Financial Services Co. MA (1.04%) and Morgan Stanley (0.91%). Company insiders that own Pfizer stock include Albert Bourla, Alexander R Mackenzie, Anthony J Maddaluna, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Institutional Ownership Trends for Pfizer.

Question 15

Which institutional investors are selling Pfizer stock?

Answer

PFE stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., FMR LLC, Russell Investments Group Ltd., Northern Trust Corp, Bank of New York Mellon Corp, Bank of New York Mellon Corp, Public Employees Retirement Association of Colorado and Legal & General Group Plc. Company insiders that have sold Pfizer company stock in the last year include Alexander R Mackenzie, Charles H Hill, Douglas M Lankler, Frank A Damelio, Ian C Read, Kirsten Lund-Jurgensen, Laurie J Olson, Loretta V Cangialosi, Mikael Dolsten, Rady A Johnson, Sally Susman and W Don Cornwell. View Insider Buying and Selling for Pfizer.

Question 16

Which institutional investors are buying Pfizer stock?

Answer

PFE stock was bought by a variety of institutional investors in the last quarter, including Charles Schwab Investment Advisory Inc., Dimensional Fund Advisors LP, Macquarie Group Ltd., Federated Investors Inc. PA, Jensen Investment Management Inc., Royal London Asset Management Ltd., Natixis and Fisher Asset Management LLC. View Insider Buying and Selling for Pfizer.

Question 17

How do I buy shares of Pfizer?

Answer

Shares of PFE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

Question 18

What is Pfizer's stock price today?

Answer

One share of PFE stock can currently be purchased for approximately $43.80.

Question 19

How big of a company is Pfizer?

Answer

Pfizer has a market capitalization of $259.01 billion and generates $52.55 billion in revenue each year. The biopharmaceutical company earns $21.31 billion in net income (profit) each year or $2.65 on an earnings per share basis. Pfizer employs 90,200 workers across the globe.

Question 20

How can I contact Pfizer?

Answer

Pfizer's mailing address is 235 EAST 42ND STREET, NEW YORK NY, 10017. The biopharmaceutical company can be reached via phone at 212-733-2323.

Community Ranking:		3.2 out of 5 ( )
Outperform Votes:		1,166 (Vote Outperform)
Underperform Votes:		640 (Vote Underperform)
Total Votes:		1,806